Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First report of a homozygous complete deletion of the carboxyl ester lipase gene (CEL).

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

DNA methylation signatures associated with bipolar disorder in peripheral blood improve prediction models.

EBioMedicine·2026
Same author

Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders.

The international journal of neuropsychopharmacology·2026
Same author

International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.

United European gastroenterology journal·2026
Same author

Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study.

The Lancet. Oncology·2025
Same author

Patients' and healthcare professionals' experiences with implementing the Rosa chatbot in mainstream genetic testing for hereditary breast and ovarian cancer.

Journal of genetic counseling·2025

Related Experiment Video

Updated: Jun 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Is pharmacogenetic CYP2D6 testing useful?

Hildegunn Høberg Vetti1, Anders Molven, Aud K H Eliassen

  • 1Centre for Medical Genetics and Molecular Medicine, Haukeland University Hospital, 5021 Bergen, Norway. hildegunn.hoeberg.vetti@helse-bergen.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 27, 2010
PubMed
Summary
This summary is machine-generated.

Routine CYP2D6 genotyping in a diagnostic lab found ultrarapid metabolizers more often in patients than controls. However, CYP2D6 genotype rarely explained patient drug response issues, highlighting the need for clear testing indications.

Related Experiment Videos

Last Updated: Jun 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenetics
  • Clinical Diagnostics
  • Drug Metabolism

Background:

  • Pharmacogenetic testing aids in understanding drug response variations.
  • Clinical utility data for pharmacogenetic methods remains limited.
  • This study evaluated routine CYP2D6 genotyping in a diagnostic laboratory setting.

Purpose of the Study:

  • To systematically categorize experiences with routine CYP2D6 genotyping.
  • To assess the clinical relevance of CYP2D6 genotype in patient populations.

Main Methods:

  • Retrospective analysis of 325 patient samples undergoing CYP2D6 genotyping.
  • Classification of samples into indication groups based on clinical data.
  • Testing for prevalent non-functional CYP2D6 alleles and ultrarapid metabolizer gene duplications, compared to 100 healthy controls.

Main Results:

  • A significantly higher proportion of ultrarapid metabolizers (4.0%) was observed in patients versus controls (0%, p=0.045).
  • No significant difference in the percentage of poor metabolizers between patient (8.3%) and control (6.0%) groups (p=0.528).
  • Ultrarapid metabolizers were most frequent in patients using known CYP2D6 substrates.

Conclusions:

  • CYP2D6 genotype analysis infrequently explained patient-reported side effects or lack of drug efficacy.
  • Unclear indications for genetic testing may limit clinical utility.
  • CYP2D6 genotype is one of multiple factors influencing individual drug response.